



Eastern
Health

FAX TRANSMISSION

Office of Dr. Robert Williams
Vice-President, Quality, Diagnostic and Medical Services
Eastern Health

Administration, Level 1
Health Sciences Centre
300 Prince Phillip Drive
St. John's, Newfoundland
A1B 3V6
Main Phone: (709) 777-1308
Fax: (709) 778-6307

*May 2
forwarded +
to Peter Dawe to
be reviewed
to receive*

CONFIDENTIAL

To: Pam Elliott
Heather Predham

Date: May 2, 2006

Pages: 3, Including this cover sheet.

From: Dr. Robert Williams
Vice President, Quality, Diagnostic and Medical Services

RE: Letter to Peter Dawe

Pam, Heather,

Dr. Williams would like to both to review the attached letter and provide him with comments before he sends.

Thanks,
Denise

*May 3
forwarded to G. Tilley
(Answer by fax)*



Eastern
Health

Office of Dr. Robert Williams
Vice President
Quality, Diagnostic and Medical Services
c/o Room 1352, Administration
General Hospital Site
300 Prince Philip Drive
St. John's, NL A1B 3V6
Phone: 709-777-1308 Fax: 709-778-6307
E-mail: robert.williams@easternhealth.ca
www.easternhealth.ca

DRAFT

April 27, 2006

Mr. Peter Dawe
Executive Director
Canadian Cancer Society
Newfoundland Division
ADDRESS

Dear Peter:

I am writing in follow up to discussions we've had in the past and our most recent discussion of today's date.

I certainly strongly support your endeavours to get the issue of hormone receptor testing on the national agenda with a view to improving the quality and reproducibility of these tests across the country. The results of these tests are being relied on as important factors in determining treatment for breast cancer patients.

I've attached a dossier of the literature that we have reviewed here in Eastern Health with respect to methodologies and outcomes with respect to estrogen and progesterone receptor testing. As you can see from other jurisdictions, the accuracy/reproducibility/reliability has been called into question. It would seem reasonable that there be some kind of mechanism put in place nationally to monitor labs from a quality perspective who provide this testing. I know there has been discussion within the ranks of the Canadian Association of Pathologists with respect to this matter, and further follow up, I hope, will take place at their national meetings which are coming up this summer. They are a national voluntary organization who are not in the position to mount any service with respect to quality review of these testing procedures, but I am sure would be willing to participate in discussions with a view to furthering the quality agenda in this respect.

I would also hope that discussions could take place in the Oncology community on this issue, as Oncologists need reliable testing to offer optimal treatment to patients with breast cancer. Also, the literature indicates that there are variable cut-off points with respect to when hormonal therapy will be offered depending on the results of ER and PR testing. I think this is another issue that needs national discussion to achieve consensus.

Any efforts your national association could offer as you move forward with a national cancer strategy to encompass enhancing quality in this important area should be pursued.

As I advised you, our two consultants have revisited the Province to review our efforts here, and once we receive their reports, we will be making a decision concerning reinstating immunohistochemical testing within the Laboratory services here in St. John's. Before we reinstitute testing, we will be doing an update and briefing session, and I would like to extend to you an opportunity to be involved in that process.

...2

Mr. P. Dawe